EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations.

Autor: Nast A; Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany., Smith C; St John's Institute of Dermatology, London, UK., Spuls PI; Academic Medical Centre Amsterdam, Amsterdam, Netherlands., Avila Valle G; Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany., Bata-Csörgö Z; University of Szeged, Szeged, Hungary., Boonen H; Office-Based Dermatology Practice, Geel, Belgium., De Jong E; Radboud University medical centre, Nijmegen, Netherlands., Garcia-Doval I; Unidad de Investigación, Fundación Piel Sana AEDV, Madrid, España., Gisondi P; University of Verona, Verona, Italy., Kaur-Knudsen D; University hospital Copenhagen, København, Denmark., Mahil S; Guy's and St Thomas' NHS Foundation Trust, London, UK., Mälkönen T; Helsinki University Central Hospital, Helsinki, Finland., Maul JT; Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland., Mburu S; International Federation of Psoriasis Associations (IFPA)., Mrowietz U; Universitätsklinikum Schleswig-Holstein, Kiel, Germany., Reich K; Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Remenyik E; University of Debrecen, Debrecen, Hungary., Rønholt KM; Aarhus University Hospital, Aarhus N, Denmark., Sator PG; Municipal Hospital Hietzing, Vienna, Austria., Schmitt-Egenolf M; Dermatology, Department of Public Health & Clinical Medicine, Umeå University, Umeå, Sweden., Sikora M; Department of Dermatology, Medical University of Warsaw, Warszawa, Poland., Strömer K; Office-Based Dermatology Practice, Mönchengladbach, Germany., Sundnes O; Oslo University Hospital, Oslo, Norway., Trigos D; International Federation of Psoriasis Associations (IFPA)., Van Der Kraaij G; Academic Medical Centre Amsterdam, Amsterdam, Netherlands., Yawalkar N; Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Dressler C; Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Jazyk: angličtina
Zdroj: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2020 Nov; Vol. 34 (11), pp. 2461-2498.
DOI: 10.1111/jdv.16915
Abstrakt: This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.
(© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.)
Databáze: MEDLINE
Externí odkaz: